Physician profile
James Andre Visser
NPI 1548353048
$4,566.46
in general payments reported to CMS, 2019-2025
37 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $278 · 2021: $399 · 2022: $499 · 2023: $554 · 2024: $1,349 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,993 · Education: $73.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,993.40 |
| Education | $73.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $714.16 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $546.85 | 2019-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $379.03 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $347.48 | 2020-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $326.35 | 2019-2025 | Farxiga, Lokelma |
| Genzyme Corporation | $268.55 | 2019-2025 | |
| Travere Therapeutics, INC. | $189.95 | 2022-2025 | |
| Akebia Therapeutics INC | $170.96 | 2019-2022 | |
| Chiesi USA, INC. | $150.65 | 2024-2025 | Elfabrio |
| Novo Nordisk INC | $141.21 | 2021-2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $117.53 | 2019-2022 | |
| Daiichi Sankyo INC. | $106.90 | 2020-2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $98.73 | 2020-2025 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $90.74 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.53 | 2022-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Visser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.